MCM
IBB icon

Mill Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Mill Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$13K – 132
2022
Q1 		$13K Buy
+100
New +$13K ﹤0.01% 133

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Mill Capital Management's IBB Position: Q2 2022 in Review

Mill Capital Management sold out of iShares Biotechnology ETF (IBB) in Q2 2022, closing a stake of 100 shares — an estimated $13K sold.

Mill Capital Management first reported a position in IBB in Q1 2022 and held it in 1 quarter. The position peaked at $13K in Q1 2022. 858 funds tracked by Wall St. Rank hold IBB as of Q2 2022.

  • Mill Capital Management reported no remaining iShares Biotechnology ETF position as of Q2 2022 after selling out during the quarter.
  • Mill Capital Management sold 100 iShares Biotechnology ETF shares in Q2 2022, an estimated $13K.
  • Mill Capital Management first reported a position in iShares Biotechnology ETF in Q1 2022 and held it in 1 quarter.
  • Mill Capital Management's iShares Biotechnology ETF position peaked at $13K in Q1 2022.
  • 858 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2022.

Based on Mill Capital Management's 13F filing for Q2 2022, filed 29 Jul 2022.